Biomedical Advanced Research and Development Authority (BARDA) has modified its contract with AVITA Medical Inc (NASDAQ:RCEL) to support its clinical trial in soft tissue reconstruction.
- AVITA Medical is currently completing a pivotal trial to use the RECELL System for soft tissue reconstruction.
- Currently, the RECELL System is indicated in the U.S. to treat acute thermal burns.
- Related: AVITA Medical Inks Supply Pact With Premier For RECELL System.
- The clinical trial will compare the clinical performance of conventional autografting to that of widely meshed autografting with the RECELL System on acute non-burn full-thickness skin defects to demonstrate that less donor skin is needed without compromising healing outcomes.
- Topline data from the trial will be shared later this year.
- Price Action: RCEL shares closed 4.09% lower at $7.74 on Monday.
